登录 | 注册    关注公众号  
微信公众号
搜索
 > 【BAFFR】

BAFFR信息

英文名称:B-cell activating factor receptor
中文名称:B细胞活化因子受体
靶点别称:BAFFR,B Cell-Activating Factor Receptor,Prolixin,BROMIX,CD268,Tumor Necrosis Factor Receptor Superfamily, Member 13C,Tumor Necrosis Factor Receptor Superfamily Member 13C,BR3,CVID4,CD268 Antigen,BAFF Receptor,B-Cell Activation Factor Receptor,BAFF-R,TNF Receptor Superfamily Member 13C,BLyS Receptor 3,B-Cell-Activating Factor Receptor,TNFRSF13C
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

Licensing 项目合作

项目名称 适应症 项目阶段 合作需求
BIA202201 B细胞恶性肿瘤、自身免疫性疾病 CMC阶段 寻求项目转让或者合作开发

BAFFR 分子别名

BAFFR,TNFRSF13C,BROMIX,CD268,CVID4,prolixin,BAFF-R

BAFFR 分子背景

BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

BAFFR 前沿进展

BAFFR临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Ianalumab VAY-736; NOV-5 临床三期 Morphosys Ag, 诺华制药 原发性纵隔B细胞淋巴瘤, 慢性淋巴细胞白血病, 天疱疮, 血小板减少, 非霍奇金淋巴瘤, 自身免疫性肝炎, 系统性红斑狼疮, 套细胞淋巴瘤, 滤泡中心淋巴瘤, 边缘带B细胞淋巴瘤, 自身免疫性溶血性贫血, 多发性硬化, 狼疮肾炎, 类风湿关节炎, 特发性肺纤维化, Sjtoegren综合征, 特发性血小板减少性紫癜, 血液肿瘤 详情
ESG-206 ESG-206 临床一期 上海诗健生物科技有限公司 淋巴瘤 详情
AUR-200 AUR-200 临床一期 Thunderbolt Pharma Inc 自身免疫疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定